24/02/2026 – AB Science announced the identification of a potential biomarker for assessing the activity of masitinib in pathological microglial involvement in Amyotrophic Lateral Sclerosis (ALS) Download PDF Post navigationPreviousPrevious post:FDA granted the status of Minor Use in Major Species (MUMS) for Masivet®NextNext post:Update on clinical development programRelated PostsAnnual financial results as of 31 December, 202513 May 2026AB Science announces the successful completion of a EUR 3.2 million private placement29 April 2026AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors27 April 2026New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients20 April 2026Update on clinical development program16 April 2026FDA granted the status of Minor Use in Major Species (MUMS) for Masivet®9 February 2026
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors27 April 2026
New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients20 April 2026
